Condition
Plexiform Neurofibromas (PN)
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT02407405Phase 2Active Not Recruiting
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
NCT06763315Phase 2Not Yet RecruitingPrimary
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
Showing all 2 trials